Evidence map›Paper›PMID 28254470›Full record

ArticleThe Journal of allergy and clinical immunology2017

Tackling inpatient penicillin allergies: Assessing tools for antimicrobial stewardship.

Kimberly G Blumenthal, Paige G Wickner, Shelley Hurwitz, Nicholas Pricco, Alexandra E Nee, Karl Laskowski, Erica S Shenoy, Rochelle P Walensky

Open access · hybridAbstract read
In one paragraph

Article in The Journal of allergy and clinical immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 4 pooled it
15.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 4 syntheses or guidelines pooled it, 144 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Penicillin allergy delabeling in long-term care facilities: if not now, then when?Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025
    Article
  14. Developing and disseminating an electronic penicillin allergy de-labelling tool using the model for improvement framework.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2024
    Article
  15. Article
  16. Article
  17. How to Define and Manage Low-Risk Drug Allergy Labels.The journal of allergy and clinical immunology. In practice · 2024
    Review
  18. Article
  19. Don't we overestimate drug allergies in children?International journal of occupational medicine and environmental health · 2023
    Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Kimberly G BlumenthalDivision of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Mass; Edward P. Lawrence Center for Quality and Safety, Massachusetts General Hospital and the Massachusetts General Professional Organization, Boston, Mass; Harvard Medical School, Boston, Mass. Electronic address: kblumenthal1@partners.org.
Paige G WicknerHarvard Medical School, Boston, Mass; Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Brigham and Women's Hospital, Boston, Mass.
Shelley HurwitzHarvard Medical School, Boston, Mass; Department of Medicine, Brigham and Women's Hospital, Boston, Mass.
Nicholas PriccoUniversity of Minnesota Medical School, Minneapolis, Minn.
Alexandra E NeeNew York Medical College, Valhalla, NY.
Karl LaskowskiHarvard Medical School, Boston, Mass; Department of Medicine, Brigham and Women's Hospital, Boston, Mass.
Erica S ShenoyMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass; Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, Mass; Infection Control Unit, Massachusetts General Hospital, Boston, Mass.
Rochelle P WalenskyMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass; Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, Mass.
Harvard University · USBrigham and Women's Hospital · USMassachusetts General Hospital · USNew York Medical College · USUniversity of Minnesota Medical Center · US

Funding

Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2M
The Clinical and Economic Impact of Penicillin AllergyK01AI125631 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BLUMENTHAL, KIMBERLY GOLD · 2016 to 2021
$779k
NCATS NIH HHS UL1 TR001102NIAID NIH HHS K01 AI125631
6 · The paper itself

Abstract

backgroundReported penicillin allergy rarely reflects penicillin intolerance. Failure to address inpatient penicillin allergies results in more broad-spectrum antibiotic use, treatment failures, and adverse drug events.

objectiveWe aimed to determine the optimal approach to penicillin allergies among medical inpatients.

methodsWe evaluated internal medicine inpatients reporting penicillin allergy in 3 periods: (1) standard of care (SOC), (2) penicillin skin testing (ST), and (3) computerized guideline application with decision support (APP). The primary outcome was use of a penicillin or cephalosporin, comparing interventions to SOC using multivariable logistic regression.

resultsThere were 625 patients: SOC, 148; ST, 278; and APP, 199. Of 278 ST patients, 179 (64%) were skin test eligible; 43 (24%) received testing and none were allergic. In the APP period, there were 292 unique Web site views; 112 users (38%) completed clinical decision support. Although ST period patients did not have increased odds of penicillin or cephalosporin use overall (adjusted odds ratio [aOR] 1.3; 95% CI, 0.8-2.0), we observed significant increased odds of penicillin or cephalosporin use overall in the APP period (aOR, 1.8; 95% CI, 1.1-2.9) and in a per-protocol analysis of the skin tested subset (aOR, 5.7; 95% CI, 2.6-12.5).

conclusionsBoth APP and ST-when completed-increased the use of penicillin and cephalosporin antibiotics among inpatients reporting penicillin allergy. While the skin tested subset showed an almost 6-fold impact, the computerized guideline significantly increased penicillin or cephalosporin use overall nearly 2-fold and was readily implemented.

Indexed as

Drug UtilizationPractice Guidelines as TopicAgedAged, 80 and overAnti-Bacterial AgentsCephalosporinsDecision Support TechniquesDrug HypersensitivityFemaleHumansInpatientsMaleMiddle AgedPenicillinsSkin TestsStandard of CareAnti-Bacterial AgentsCephalosporinsPenicillinscomputerized guidelinedecision supportskin testStewardshiptest dose

Identifiers

PMID28254470
PMCPMC5496780
OpenAlexW2593059627

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.